Press Room

News / Aug 08, 2022

Approved gas reduction in the EU

News release, 8 August 2022

hovione logo on a brick wall in Cork Site

Last week, in an effort to increase energy security in the European Region and prepare for possible disruptions of gas supplies from Russia, the European Union (EU) member states reached a political agreement on a voluntary reduction of natural gas demand by 15% this winter. To respond to this engagement, each Member State will need to define the measures it will adopt between the 1st of August 2022 and the 31st of March 2023. To reflect the individual situations of Member States, some exceptions are expected, however, at this date details are still unknown. 

 

Although we do not expect the Hovione manufacturing operations to be affected, it is not unreasonable to expect that some of our suppliers of raw and starting materials may be impacted.  We are therefore preparing a risk mitigation plan, which includes strengthening our supply chain to reduce the impact that any disruption may have on our activity. 

 

One option we decided to offer to our customers is to purchase raw materials early and store them closer to our manufacturing site. If you are interested in exploring this option or have questions or alternate proposals, please contact your Account Manager. 

 

As your partner, we are committed to employing our best efforts to mitigate any serious impact that might get in the way of our delivering the products and services requested by our customers.

 

Thank you for your trust and collaboration through these unprecedented challenges. 

 

Patients need us. We are In it for life.

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025